While our study provides evidence using LUAD cells harboring KRAS or EGFR mutations and KRASG12D-driven lung adenocarcinoma, it would be valuable to investigate whether this mechanism occurs in other cancers with different oncogenic changes that consistently activate ERK. The gene discussed is EGFR; the disease is cancer.